Latest News

Xention Initiates Human Clinical Testing of New Atrial Fibrillation Drug.

27 July 2011.  XENTION LTD., the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, announced today that it has initiated phase 1 clinical development of XEN-D0103, an innovative new drug for the treatment and prevention of atrial fibrillation, the most common form of heart arrhythmia. Xention’s new agent...


Opsona Therapeutics announces Phase 1 clinical trial.

5 July 2011, DUBLIN, Ireland.  Opsona Therapeutics, a biotechnology company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases today announced that it has initiated a phase 1 clinical trial in healthy volunteers with its lead drug candidate OPN-305.  This is a first-in-human study with OPN-305. OPN-305 is a humanised IgG4 monoclonal(...




< back to home page